Highlights and Quick Summary
- Repayment/Issuance of Debt (Net) for the quarter ending December 30, 2020 was $-205 Thousand (a -Infinity% decrease compared to previous quarter)
- Year-over-year quarterly Repayment/Issuance of Debt (Net) decreased by -100.82%
- Annual Repayment/Issuance of Debt (Net) for 2020 was $24.8 Million (a -78.1% decrease from previous year)
- Annual Repayment/Issuance of Debt (Net) for 2019 was $113 Million (a 5859.21% increase from previous year)
- Twelve month Repayment/Issuance of Debt (Net) ending December 30, 2020 was $24.8 Million (a -0.82% decrease compared to previous quarter)
- Twelve month trailing Repayment/Issuance of Debt (Net) decreased by -82.06% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
| 30 Dec '20 | 29 Sep '20 | 29 Jun '20 | 30 Mar '20 |
|---|---|---|---|
| $24.8 Million | $25 Million | $25 Million | $138 Million |
Visit stockrow.com/PHAT
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Repayment/Issuance of Debt (Net) of Phathom Pharmaceuticals, Inc.
Most recent Repayment/Issuance of Debt (Net)of PHAT including historical data for past 10 years.Interactive Chart of Repayment/Issuance of Debt (Net) of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2020 | $-0.21 | $0.0 | $0.0 | $25.0 | $24.8 |
| 2019 | – | $0.0 | $0.0 | $113.17 | $113.23 |
| 2018 | $1.05 | $0.85 | – | – | $1.9 |
Business Profile of Phathom Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.